- Home
- PSFE vs BCYC Comparison
PSFE vs BCYC Comparison
Compare PSFE & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSFE | BCYC |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United Kingdom | United Kingdom |
| Employees | 2900 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.7M | 360.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSFE | BCYC |
|---|---|---|
| Price | $7.30 | $5.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $10.15 | ★ $17.56 |
| AVG Volume (30 Days) | ★ 476.6K | 335.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $5.03 |
| 52 Week High | $18.15 | $10.59 |
Technical Indicators
Market Signals| Indicator | PSFE | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 39.62 |
| Support Level | $6.58 | $5.03 |
| Resistance Level | $7.39 | $5.90 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 71.16 | 18.95 |
Price Performance
Historical ComparisonAbout PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.